The firm cited a new study from the Washington University School of Medicine which showed AZD7442 maintained the effective resistance against Omicron variant, including its sub-variants BA.1, BA.1.1 and BA.2.1.
in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines. John Perez, senior vice president, Head of Late Development, Vaccines & Immune Therapies of AstraZeneca, said the data showed that AZD7442 reduced viral burden and limited inflammation caused by Omicron.
The US national public health agency said on Monday the BA.2 sub-variant of Omicron was estimated to account for nearly three of every four coronavirus variants in the country.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: